One of the greatest offerings we give as an e-signature company is the ability to reduce the amount of paper and precious time it takes for a clinical trial to go to market. On Tuesday, December 1 at 1:00 p.m. EST, SIGNiX will partner with the Society for Clinical Research Sites to present an informational webinar.Read More
Life Sciences News
As the only e-signature vendor exhibiting during the Global Site Solutions Summit, SIGNiX had the unique opportunity to collect every detail of the needs of clinical investigative sites. Global Site Solutions Summit, a conference to advance the ethical and efficient conduct of clinical research and to encourage and build strong site partnerships, was held in Amelia Island, Florida October 8-11.Read More
SIGNiX traveled to Boston this month to exhibit at Dpharm’s Disruptive Innovations Conference for Life Sciences. Disruptive Innovations is about creating efficiency and utilizing technology within the Life Sciences industry.Read More
SIGNiX is excited to be a part of a conference that is bringing innovations to the Life Sciences community. This year, we will be joining the 5th annual DPharm: Disruptive Innovations to Advance Clinical Trials conference to aid in the advance of clinical trials by speeding up the signature process and cutting down on the cost of paper processes.Read More
Using e-signatures to expedite transactions is one of the surest ways to generate immediate efficiencies within clinical trials. In fact, Sarah Cannon Research Institute, one of the largest clinical research organizations in the world, sped up its highly regulated signing process by up to 94 percent by using SIGNiX’s Independent E-Signatures™, and it expects to save $250,000 in its first year to boot!Read More
If you haven’t heard, there was a lot to love about DIA 2015. One of our personal highlights was watching Peyton Hale, director of application services at HCA, along with SIGNiX’s own John Harris, SVP of product management, speak to the DIA crowd about Sarah Cannon Research Institute’s success with the adoption of SIGNiX Independent E-SignaturesTM.
It was a great year to attend DIA’s 2015 Annual Meeting, an event that unites life sciences professionals with the shared goal of nurturing innovation. We had the chance to travel to our nation’s capitol and exhibit at the event. Here are our key takeaways from the conference:Read More
We are excited to announce that we are a “20 Most Promising Pharma and Life Sciences Technology Solution Provider in 2015” selected by CIOReview.
This annual list showcases the best vendors and consultants who provide top technology solutions to these industries. A panel of experts and members of CIOReview’s editorial board select companies for the list, and SIGNiX is honored to be recognized.Read More
We’re happy to announce that Sarah Cannon Research Institute (SCRI), a global leader in clinical research, has sped up its clinical trial process and saved a lot of money after piloting an e-signature program for its clinical trials.Read More
In many years dealing with Part 11 compliance, I have often seen confusion over exactly what constitutes an “Electronic Signature.” The FDA’s definition is found in 21 CFR Part 11; Electronic Records, Electronic Signatures, the regulations specifying the FDA’s requirements for using records and signatures in electronic form to meet the record-keeping requirements of Agency regulations in the Life Sciences industry.Read More
Tags: 21 CFR Part 11